NovoCure Limited (FRA:038)

Market Cap	1.17B -57.8%
Revenue (ttm)	547.41M +11.2%
Net Income	-151.41M
EPS	-1.37
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Average Volume	76
Open	10.59
Previous Close	10.84
Day's Range	10.59 - 10.59
52-Week Range	8.63 - 24.20
Beta	n/a
RSI	37.63
Earnings Date	Feb 27, 2026

About NovoCure

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. The company’s TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was inc...

• Industry: Electromedical and Electrotherapeutic Apparatus
• Founded: 2000
• Employees: 1,488
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 038

Financial Performance

In 2024, NovoCure's revenue was $605.22 million, an increase of 18.82% compared to the previous year's $509.34 million. Losses were -$168.63 million, -18.55% less than in 2023.

Financial numbers in USD